Landscape Capital Management L.L.C. Decreases Stake in PetIQ, Inc. (NASDAQ:PETQ)

Landscape Capital Management L.L.C. lessened its stake in shares of PetIQ, Inc. (NASDAQ:PETQFree Report) by 39.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 56,832 shares of the company’s stock after selling 37,400 shares during the period. Landscape Capital Management L.L.C.’s holdings in PetIQ were worth $1,749,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of PetIQ by 4.9% during the first quarter. Vanguard Group Inc. now owns 2,252,842 shares of the company’s stock valued at $41,182,000 after buying an additional 105,083 shares during the last quarter. Boston Partners raised its stake in shares of PetIQ by 6.8% in the first quarter. Boston Partners now owns 1,067,677 shares of the company’s stock worth $19,124,000 after purchasing an additional 67,797 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of PetIQ by 107.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 5,221 shares of the company’s stock worth $91,000 after purchasing an additional 2,704 shares during the period. CWM LLC boosted its position in PetIQ by 86.2% in the second quarter. CWM LLC now owns 1,251 shares of the company’s stock valued at $28,000 after buying an additional 579 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in PetIQ during the 2nd quarter worth approximately $144,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

PetIQ Price Performance

NASDAQ:PETQ opened at $30.98 on Friday. The company has a 50 day moving average price of $30.89 and a 200-day moving average price of $26.28. PetIQ, Inc. has a 1-year low of $15.09 and a 1-year high of $31.06. The firm has a market cap of $925.99 million, a price-to-earnings ratio of 79.44 and a beta of 1.73. The company has a debt-to-equity ratio of 1.68, a current ratio of 2.58 and a quick ratio of 1.68.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PETQ. William Blair lowered shares of PetIQ from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 7th. Truist Financial downgraded PetIQ from a “buy” rating to a “hold” rating and increased their price target for the stock from $30.00 to $31.00 in a research report on Thursday, August 8th.

Check Out Our Latest Stock Report on PETQ

PetIQ Company Profile

(Free Report)

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.

Read More

Want to see what other hedge funds are holding PETQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetIQ, Inc. (NASDAQ:PETQFree Report).

Institutional Ownership by Quarter for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.